 |
● |  |
● |  |
Some FDA-approved medical devices age more safely than others. That’s no less true of AI-enabled technologies than of any others. In fact, the need for vigilance around embedded AI models may be more pressing than the medical-device norm.
The agency makes this clear in guidance issued as a detailed draft in progress this week.
“The performance of AI-enabled medical devices deployed in real-world environments may change or degrade over time, presenting a risk to patients,” FDA states in the document. “In general, manufacturers should have a postmarket performance monitoring plan to help identify and respond to changes in performance in a postmarket setting.”
The underlying idea is to push device makers to include long-term plans for monitoring performance as soon as they submit products for market approval. This approach, FDA suggests, will help cut chances of recalls over time while supporting the agency’s ongoing evaluation of AI risk controls.
The draft document—“Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations”—is primarily aimed at device manufacturers and FDA staff. It’s open for comments until April 7. Here are some key excerpts.
In addition, sponsors must develop and implement plans for comprehensive risk-analysis programs and documentation consistent with established Quality System Regulation Practices to manage risks related to undesirable changes in device performance for AI-enabled medical devices.
Further, manufacturers must monitor device performance and report to FDA information about deaths, serious injuries and malfunctions.
As such, their performance can be particularly sensitive to changes in data inputs.
Changes in device performance may originate from many factors, such as changes in patient populations over time, disease patterns or data drift from other changes.
It may not be possible to completely control risks with development and testing activities performed in premarket conditions (prior to device authorization and deployment).
FDA recognizes that the environments in which medical devices are deployed cannot be completely controlled by the device manufacturer.
Rather, as part of ongoing risk management, it is important for device manufacturers to consider the impact of these factors (e.g., data drift) on the safety and effectiveness of the device.
Additional information about performance management processes may be helpful for FDA to determine whether risks have been adequately identified, addressed and controlled.
Sponsors are encouraged to obtain FDA feedback on the plan through the Q-Submission Program.
For a 510(k) submission, FDA generally does not require such plans regarding devices for which a performance monitoring plan is not a special control for the particular device type.
In some cases, FDA may establish a special control for the device type going forward. Further, for a PMA, a performance monitoring plan may be a condition of approval. However, sponsors may opt to include information regarding the performance monitoring plan in any submission for an AI-enabled device.
A robust performance monitoring plan includes proactive efforts to capture device performance after deployment.
Announcement here, document here.
Access the 2024 Executive Handbook: Ten Transformative Trends in Healthcare – What was top of mind for healthcare executives this year? What trends will shape 2025?
Nabla’s Chief Medical Officer, Dr. Ed Lee, MD, MPH, was recently interviewed for the 2024 Executive Handbook: Ten Transformative Trends in Healthcare, offering his perspective on how AI is enhancing clinical workflows and setting the stage for the future of patient care.
From shifting federal healthcare policies to the emergence of disruptors beyond traditional health systems and pressing cybersecurity challenges, discover the key insights shaping the industry.
Download the full handbook here.
Assistant or Associate Dean, Health AI Innovation & Strategy – UCLA Health seeks a visionary academic leader to serve as its Assistant or Associate Dean for Health AI Innovation and Strategy and Director for the UCLA Center for AI and SMART Health. This unique position offers the opportunity to shape and drive AI vision and strategy for the David Geffen School of Medicine (DGSOM) and ensure translation of innovation in our renowned Health system. This collaborative leader will work with academic leadership, faculty, staff and trainees to harness the power of AI to transform biomedical research, decision and implementation science, and precision health. Learn more and apply at:
https://recruit.apo.ucla.edu/JPF09997 (tenured track)
https://recruit.apo.ucla.edu/JPF10032 (non-tenured track)
Buzzworthy developments of the past few days.
Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.
Interested in reaching our audiences, contact our team
*|LIST:ADDRESSLINE|*
You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here
Contact Us | Unsubscribe from all | Privacy Policy
© Innovate Healthcare, a TriMed Media brand